Atlas Venture raises USD 250 Million for investing in later-stage
Massachusetts-based Atlas Venture has raised USD 250 million for later-stage investments. The fund will allow the VC shop to bolster its startups through series B and beyond. The early-stage operation has bolstered a couple of startups like Padlock and Unum Therapeutics, to IPOs and trade sales. Atlas Venture Opportunity Fund I (AVOF I) is the VC shop’s remedy for financial requirements. Atlas Venture has USD 250 million to support the portfolio companies as they reach series B and beyond.
Harpoon files USD 86 Million IPO for funding its T-cell engager platform
Harpoon Therapeutics declared for going public with a USD 86.25 million IPO to bolster its portfolio of early-stage T-cell engagers aimed at solid
Boston Scientific bags Millipede and its device for USD 325 Million
Millipede and Boston Scientific inked the agreement, Boston Scientific gave USD 90 million for a portion of the mitral regurgitation startup’s shares and now the device maker is remunerating USD 325 million to pick up the rest shares of Millipede. Boston Scientific could choose to give USD 325 million and commit to remunerate a USD 125 million commercial